Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Brusky Sean P. 2. Date of Event Requiring Statement (Month/Day/Year) 03/05/2026 3. Issuer Name and Ticker or Trading Symbol Prelude Therapeutics Inc [PRLD] (Last) (First) (Middle) C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Business Officer 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) WILMINGTON, DE 19805 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 100,000 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	04/30/2034	Common Stock	300,000	$0	D
Employee Stock Option (Right to Buy)	(2)	02/03/2035	Common Stock	175,000	$0	D
Employee Stock Option (Right to Buy)	(3)	02/03/2036	Common Stock	275,000	$0	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Brusky Sean P. C/O PRELUDE THERAPEUTICS INCORPORATED 175 INNOVATION BOULEVARD WILMINGTON, DE 19805			Chief Business Officer

Signatures

/s/ Bryant Lim, as attorney-in-fact for the Reporting Person		03/19/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Stock option grant awarded on May 1, 2024 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on May 1, 2025, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
(2)	Stock option grant awarded on February 4, 2025 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on February 4, 2026, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
(3)	Stock option grant awarded on February 4, 2026 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on February 4, 2027, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Remarks: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.